Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)

NCT02240667 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02240667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
September 18, 2014
Completion date
December 31, 2017
Enrollment
1,506 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation